Clinical Trials and Research News Weekly Roundup | Ivermectin Repurposing for COVID-19: The Israeli Perspective (Israel 2020-12-07) TrialsSiteNews video
‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’: Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective. ” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP). ” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists. ”
Professor Schwartz is running the Israel - ivermectin trial.
[-] TrumpLyftAlles | 1 points | Dec 08 2020 03:08:49
Accompanying text:
‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’: Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective. ” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP). ” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists. ”
Professor Schwartz is running the Israel - ivermectin trial.
permalink